British doctors presented the results of the use of dexamethasone for patients with coronavirus. It is 30% decreases mortality among critically ill patients that are connected to the ventilator.
the Results of clinical trials of steroid drug dexamethasone in the treatment of coronavirus infection in the UK are scientific breakthrough. This was stated by Director General of the world health organization (who), Tedros of Ghebreyesus.
“This is the first drug that showed a decrease in mortality among patients with COVID-19 who require mechanical ventilation and oxygen support,” Ghebreyesus said in a meeting in Geneva.
According to preliminary data, the use of dexamethasone showed a decrease in mortality among patients on mechanical ventilation by one-third, and among patients who are on oxygen support for 20%.
Dexamethasone is a steroid that is used with the 60-ies of the last century as an anti-inflammatory. It is used, including in Oncology. The organization notes that the positive effect of steroid was observed only in patients with severe disease.
While researchers from Oxford University revealed the preliminary results of the use of the drug. In the near future who is waiting for a full report to update their recommendations for treatment COVID-19.
In late may, the who stopped testing anti-malaria treatment of hydroxychloroquine as a method of treating coronavirus infection. The decision was taken after the respected medical publication the Lancet published the results of a study which referred to the increased mortality among patients taking hydroxychloroquine. The trial took place in ten countries. Now scientists evaluate its safety in the treatment of COVID-19.
Earlier in June, the Russian direct investment Fund (RDIF) and a group of companies “Chemrar” reported that put in the hospital the first batch of domestic preparation against coronavirus infection, “Avidavit”.
the Medicine has received medical institutions in Moscow, Leningrad, Novgorod, Kirov and Nizhny Novgorod regions, as well as hospitals of the Republic of Tatarstan and Ekaterinburg. “Aviewer” will be used exclusively under medical supervision and become free of medical insurance.
